黎小妍;何琼;徐乐加;曲彩红;张平;
LI Xiao-yan1,HE Qiong2,XU Le-jia1,QU Cai-hong1,ZHANG Ping1 (1.Department of Pharmacy,2.Department of Pathology,Third Affiliated Hospital Sun Yat-sen University,Guangzhou,Guangdong 510630,China)

• 1:中山大学附属第三医院药剂科
• 2:中山大学附属第三医院病理科

摘要(Abstract)：

目的观察口服拉米夫定治疗48周对慢性乙型肝炎(CHB)患者血清HBV-DNA水平的影响及其与肝组织学的关系,评估拉米夫定对CHB患者的疗效。方法 60例CHB患者均来自本院2009-03～2012-03住院患者,给予口服拉米夫定100 mg/d,于治疗前和治疗后应用RT-PCR检测法检测血清HBV-DNA水平,治疗48周后进行肝组织穿刺,标本进行炎症活动度分级(G)及纤维化程度分期(S)。结果拉米夫定治疗12和24周血清HBV-DNA的水平和治疗前比较没有明显差异(P>0.05),治疗36、48周后血清HBV-DNA水平较治疗前明显降低(P<0.05);治疗48周后血清HBV-DNA水平与肝组织炎症活动度(G)(r=-0.452,P=0.017)及纤维化程度(S)(r=-0.571,P=0.001)呈负相关。结论拉米夫定可以降低CHB患者血清HBV-DNA的水平;治疗48周后血清HBV-DNA水平与肝组织炎症活动度(G)分级和纤维化程度(S)分期呈负相关,该结果为拉米夫定治疗CHB患者疗效的评估提供实验依据。
Objective To observe the concentration of serum HBV-DNA in patients with chronic hepatitis B(CHB) after treated by lamivudine orally for 48 w,and evaluate the correlation between the treatment and change of liver histology.Methods A total of 60 patients of CHB who were selected from 2009-03²012-03 in the inpatients of the hospital were treated by lamivudine(oral,100 mg/d) for 48 w.The concentration of serum HBV-DNA were detected by real time PCR before and after the treatment.The liver biopsy was done at end of 48 weeks,and the samples were classified according to the inflammation activity of liver tissue.Results The concentration of serum HBV-DNA had no significant difference(P>0.05) after treated for 12 and 24 w by lamivudine,but was decreased significantly after treated for 36 and 48 w(P<0.05).Serum HBV-DNA concentration was negatively correlated with the grade of hepatic-necro inflammation(r=-0.452,P<0.05) or the stage of fibrosis(r=-0.571,P<0.05) after treated for 48 w.Conclusion The concentration of serum HBV-DNA can be significantly reduced after treated by lamivudine.There is significant negative correlation between serum HBV-DNA levels and hepatic histology change after treated by lamivudine for 48 w,which would provide experiment evidence for evaluating the effency of lamivudine.

关键词(KeyWords)： 慢性乙型肝炎;HBV-DNA定量;拉米夫定
chronic hepatitis B;HBV-DNA;lamivudine

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 黎小妍;何琼;徐乐加;曲彩红;张平;
LI Xiao-yan1,HE Qiong2,XU Le-jia1,QU Cai-hong1,ZHANG Ping1 (1.Department of Pharmacy,2.Department of Pathology,Third Affiliated Hospital Sun Yat-sen University,Guangzhou,Guangdong 510630,China)

参考文献(References)：

• [1]Merican I,Guan R,Amarapuka D,et al.Chronic hepatitisB virus infection in Asian countries[J].J GastroenterolHepatol,2000,15(12):1356-1361.
• [2]骆抗先.乙型肝炎临床与活体组织病理[M].北京:科学出版社,2001:81-86.
• [3]程明亮,杨长春.肝纤维化的基础研究及临床[M].北京:人民卫生出版社,2002:9-10.
• [4]Park JH,Park CK,Kim ES,et al.The diagnostic value ofserum hyaluronic acid,7S domain of type IV collagen andAST/ALT ratio as markers of hepatic fibrosis in chronic hep-atitis B and cirrhosis patients[J].Taehan Kan HakhoeChi,2003,9(2):79-88.
• [5]中华医学会肝脏学分会.中华医学会感染病分会.慢性乙型肝炎防治指南[J].中华传染病杂志,2005,6(23):421-431.
• [6]刘琼,谢冬英,邓洪,等.肝组织病变程度不同的慢性乙型肝炎患者血清HBsAg及HBV-DNA水平比较[J].中华临床医师杂志,2011,13(5):3799-3802.
• [7]罗瑞虹,赵志新,崇雨田,等.HBV感染与肝组织病理改变的典型相关分析[J].中山大学学报,2006,4s(27):185-187.
• [8]Chun YK,Kim JY,Woo HJ,et al.No significant correla-tion exists between core promoter mutations,viral replica-tion,and liver damage in chronic hepatitis B infection[J].Hepatology,2000,32(5):1154-1162.
• [9]李仕周,蒋永芳.HBeAg阴性和阳性慢性乙型肝炎患者血清HBV-DNA水平与肝组织炎症的关系[J].世界华人消化杂志,2006,14(33):3241-3244.
• [10]姜湘宁,王功遂,尹建军.慢性乙型肝炎患者血清HBeAg和HBV-DNA水平与肝组织病理关系的探讨[J].实用肝脏病杂志,2004,7:86-88.
• [11]朱雄鹰,谌翠蓉,娄国强.慢性乙型肝炎的临床、血清HBV-DNA与病理分度的关系[J].浙江实用医学,2004,9:88-89.
• [12]Cho SC,Lee SH,Shinn JJ,et al.HBV-DNA levels,ami-notransferase and histological activity in young male pa-tients with HBeAg positive chronic hepatitis B[J].TaehanKan Hakhoe Chi,2002,8:44-51.
• [13]Fan HM,Zhang CL,Ying RS,et al.Relationship be-tween liver pathological characteristics and serum HBeAgand HBV-DNA in 1057 patients with chronic hepatitis B[J].Zhonghua Shi Yan He Lin Chuang Bing Du Xue ZaZhi,2008,22(2):130-132.
• [14]Fung J,Lai CL,But D,et al.Prevalence of fibrosis andcirrhosis in chronic hepatitis B:implications for treatmentand management[J].Am J Gastroenterol,2008,103(6):1421-1426.
• [15]Heo JH,Heo J,Kwon DS,et al.Relationship between se-rum HBV-DNA levels and liver histology in chronic hepati-tis B[J].Korean J Gastroenterol,2003,42:220-225.
• [16]唐跃华,谢健敏,梁玉全,等.慢性乙型肝炎患者血清HBeAg、HBV-DNA与肝组织炎症关系的探讨[J].中华传染病杂志,2005,23:338-342.
• [17]Manesis EK,Papatheodoridis GV,Hadziyannis SJ.SerumHBV-DNA levels in inactive hepatitis B virus carriers[J].Gastroenterology,2002,122:2092-2093.
• [18]Dienstag JL,Goldin RD,Heathcote EJ,et al.Histologicaloutcome during long-term lamivudine therapy[J].Gastro-enterology,2003,124(1):105-117.
• [19]Schalm SW,Heathcote J,Cianciara J.et al.Lamivudineand alpha interferon combination treatment of patients withchronic hepatitis B infection:a randomised trial[J].Gut,2000,46(4):562-568.
• [20]Kweon YO,Goodman ZD,Dienstag JL,et al.Decreasingfibrogenesis:an immunohistochemical study of paired liverbiopsies following lamivudine therapy for chronic hepatitisB[J].J Hepatol,2001,35(6):749-755.
• [21]姚光弼,崔振宇,姚集鲁.等.国产拉米夫定治疗2200例慢性乙型肝炎的Ⅳ期临床试验[J].中华肝脏病杂志,2003,11(2):103-108.
• [22]赖菁,柯伟民,顾琳,等.乙型肝炎血清HBV-DNA含量与肝纤维化、实质病变程度的关系[J].胃肠病学和肝病学杂志,2009,3(18):210-212.
• [23]邵丽华,马立宪,吕卉.慢性乙型病毒性肝炎患者肝组织HBV-DNA定量与炎症活动度及细胞凋亡关系[J].临床检验杂志,2004,2(12):117.